PT-141 — Melanocortin receptor agonist (MC3R/MC4R)
Activates melanocortin-4 receptors (MC4R) in the central nervous system to enhance sexual desire through hypothalamic pathways. Unlike PDE5 inhibitors, acts on arousal/desire rather than vascular erectile function.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Melanocortin receptor agonist (MC3R/MC4R)
Mechanism of Action
Activates melanocortin-4 receptors (MC4R) in the central nervous system to enhance sexual desire through hypothalamic pathways. Unlike PDE5 inhibitors, acts on arousal/desire rather than vascular erectile function.
Regulatory Status
FDA approved (Vyleesi for premenopausal women with HSDD)
Evidence Level
High — FDA-approved based on Phase 3 RECONNECT trials